Anti-ERCC1 antibody [8F1]
| Name | Anti-ERCC1 antibody [8F1] |
|---|---|
| Supplier | Abcam |
| Catalog | ab2356 |
| Prices | $392.00 |
| Sizes | 500 µl |
| Host | Mouse |
| Clonality | Monoclonal |
| Isotype | IgG2b |
| Clone | 8F1 |
| Applications | ICC/IF ICC/IF WB IP IHC-P IHC-F FC |
| Species Reactivities | Rat, Human |
| Antigen | Recombinant full length protein corresponding to Human ERCC1 |
| Description | Mouse Monoclonal |
| Gene | ERCC1 |
| Conjugate | Unconjugated |
| Supplier Page | Shop |
Product images
ab2356 staining human tonsil by IHC-P.
ICC/IF image of ab2356 stained HepG2 cells. The cells were 4% formaldehyde fixed (10 min) and then incubated in 1%BSA / 10% normal goat serum / 0.3M glycine in 0.1% PBS-Tween for 1h to permeabilise the cells and block non-specific protein-protein interactions. The cells were then incubated with the antibody (ab2356, 1µg/ml) overnight at +4°C. The secondary antibody (green) was Alexa Fluor® 488 goat anti-mouse IgG (H+L) used at a 1/1000 dilution for 1h. Alexa Fluor® 594 WGA was used to label plasma membranes (red) at a 1/200 dilution for 1h. DAPI was used to stain the cell nuclei (blue) at a concentration of 1.43µM.
![Overlay histogram showing HeLa cells stained with ab2356 (red line). The cells were fixed with 100% methanol (5 min) and then permeabilized with 0.1% PBS-Tween for 20 min. The cells were then incubated in 1x PBS / 10% normal goat serum / 0.3M glycine to block non-specific protein-protein interactions followed by the antibody (ab2356, 1µg/1x106 cells) for 30 min at 22°C. The secondary antibody used was DyLight® 488 goat anti-mouse IgG (H+L) (ab96879) at 1/500 dilution for 30 min at 22°C. Isotype control antibody (black line) was mouse IgG2b [PLPV219] (ab91366, 2µg/1x106 cells) used under the same conditions. Acquisition of >5,000 events was performed. This antibody gave a positive signal in HeLa cells fixed with 4% paraformaldehyde (10 min)/permeabilized in 0.1% PBS-Tween used under the same conditions.](http://www.bioprodhub.com/system/product_images/ab_products/2/sub_2/14891_ERCC1-Primary-antibodies-ab2356-4.jpg)
Overlay histogram showing HeLa cells stained with ab2356 (red line). The cells were fixed with 100% methanol (5 min) and then permeabilized with 0.1% PBS-Tween for 20 min. The cells were then incubated in 1x PBS / 10% normal goat serum / 0.3M glycine to block non-specific protein-protein interactions followed by the antibody (ab2356, 1µg/1x106 cells) for 30 min at 22°C. The secondary antibody used was DyLight® 488 goat anti-mouse IgG (H+L) (ab96879) at 1/500 dilution for 30 min at 22°C. Isotype control antibody (black line) was mouse IgG2b [PLPV219] (ab91366, 2µg/1x106 cells) used under the same conditions. Acquisition of >5,000 events was performed. This antibody gave a positive signal in HeLa cells fixed with 4% paraformaldehyde (10 min)/permeabilized in 0.1% PBS-Tween used under the same conditions.
ab2356 staining ERCC1 in formalin-fixed, paraffin-embedded Human tonsil tissue by Immunohistochemistry.
Product References
ERCC1 expression as a predictive marker of cervical cancer treated with - ERCC1 expression as a predictive marker of cervical cancer treated with
Muallem MZ, Marnitz S, Richter R, Kohler C, Sehouli J, Arsenic R. Anticancer Res. 2014 Jan;34(1):401-6.
ERCC1 and the efficacy of cisplatin in patients with resected non-small cell lung - ERCC1 and the efficacy of cisplatin in patients with resected non-small cell lung
Li C, Liu M, Yan A, Liu W, Hou J, Cai L, Dong X. Tumour Biol. 2014 Dec;35(12):12707-12.
ERCC1 protein expression is associated with differential survival in - ERCC1 protein expression is associated with differential survival in
Patel MR, Zhao N, Ang MK, Stadler ME, Fritchie K, Weissler MC, Zanation AM, Harris SL, Funkhouser WK, Olshan AF, Shores CG, Hayes DN. Otolaryngol Head Neck Surg. 2013 Oct;149(4):587-95. doi:
ERCC1, defective mismatch repair status as predictive biomarkers of survival for - ERCC1, defective mismatch repair status as predictive biomarkers of survival for
Li P, Fang YJ, Li F, Ou QJ, Chen G, Ma G. Br J Cancer. 2013 Apr 2;108(6):1238-44.
Treatment-related protein biomarker expression differs between primary and - Treatment-related protein biomarker expression differs between primary and
Zajchowski DA, Karlan BY, Shawver LK. Mol Cancer Ther. 2012 Feb;11(2):492-502.
Prognostic significance of thymidylate synthase expression in the adjuvant - Prognostic significance of thymidylate synthase expression in the adjuvant
Kaira K, Okumura T, Ohde Y, Takahashi T, Murakami H, Kondo H, Nakajima T, Yamamoto N. Anticancer Res. 2011 Sep;31(9):2763-71.
DNA mismatch repair proteins are required for efficient herpes simplex virus 1 - DNA mismatch repair proteins are required for efficient herpes simplex virus 1
Mohni KN, Mastrocola AS, Bai P, Weller SK, Heinen CD. J Virol. 2011 Dec;85(23):12241-53.
Hypoxia-related protein expression and its clinicopathologic implication in - Hypoxia-related protein expression and its clinicopathologic implication in
Koo JS, Kim H. Tumour Biol. 2011 Oct;32(5):893-904.
Aging results in differential regulation of DNA repair pathways in pachytene - Aging results in differential regulation of DNA repair pathways in pachytene
Paul C, Nagano M, Robaire B. Biol Reprod. 2011 Dec;85(6):1269-78.
ERCC1 expression and outcomes in head and neck cancer treated with concurrent - ERCC1 expression and outcomes in head and neck cancer treated with concurrent
Hayes M, Lan C, Yan J, Xie Y, Gray T, Amirkhan RH, Dowell JE. Anticancer Res. 2011 Dec;31(12):4135-9.